A University of Manchester spin-out is developing nanomaterials known for their use in lighting and solar energy into new fluorescent biomarkers that could detect and improve treatment of some of the deadliest forms of cancer.
According to the Pancreatic Cancer Research Fund, 10,000 people are diagnosed with the disease each year in the UK and it is the fifth most common cause of cancer deaths. It has the lowest survival rate of all cancers, with only 3% of those diagnosed surviving more than 5 years.
Nanoco is working with Professor Sandy MacRobert and researchers at University College London on its pancreatic cancer project. This innovation could help with better diagnosis and treatment.
Nanoco Group PLC (LON:NANO) leads the world in the research, development and large-scale manufacture of heavy metal-free nanomaterials for use in displays, lighting, vertical farming, solar energy and bio-imaging.